Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.63 -7.4%	$1.68	$1.07 ▼ $6.18	$106.17M	1.19	941,811 shs	963,920 shs
BRNS Barinthus Biotherapeutics	$0.65 -6.9%	$0.63	$0.51 ▼ $2.92	$28.63M	-0.4	17,214 shs	643,146 shs
KLRS Kalaris Therapeutics	$4.44 -4.7%	$5.50	$2.14 ▼ $11.88	$110.87M	0.15	82,088 shs	140,751 shs
OTLK Oncobiologics	$0.78 -2.3%	$0.34	$0.16 ▼ $3.39	$111.31M	0.96	35.76 million shs	12.01 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	-5.38%	+0.57%	+2.33%	-63.33%	-28.74%
BRNS Barinthus Biotherapeutics	-3.11%	+1.04%	+3.66%	+12.60%	-32.77%
KLRS Kalaris Therapeutics	-1.27%	-10.04%	-12.08%	-52.55%	+50.81%
OTLK Oncobiologics	-1.85%	+7.41%	+228.84%	+91.98%	-58.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.63 -7.4%	$1.68	$1.07 ▼ $6.18	$106.17M	1.19	941,811 shs	963,920 shs
BRNS Barinthus Biotherapeutics	$0.65 -6.9%	$0.63	$0.51 ▼ $2.92	$28.63M	-0.4	17,214 shs	643,146 shs
KLRS Kalaris Therapeutics	$4.44 -4.7%	$5.50	$2.14 ▼ $11.88	$110.87M	0.15	82,088 shs	140,751 shs
OTLK Oncobiologics	$0.78 -2.3%	$0.34	$0.16 ▼ $3.39	$111.31M	0.96	35.76 million shs	12.01 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	-5.38%	+0.57%	+2.33%	-63.33%	-28.74%
BRNS Barinthus Biotherapeutics	-3.11%	+1.04%	+3.66%	+12.60%	-32.77%
KLRS Kalaris Therapeutics	-1.27%	-10.04%	-12.08%	-52.55%	+50.81%
OTLK Oncobiologics	-1.85%	+7.41%	+228.84%	+91.98%	-58.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.00	Hold	$5.50	237.42% Upside
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	513.40% Upside
KLRS Kalaris Therapeutics	2.75	Moderate Buy	$15.60	251.35% Upside
OTLK Oncobiologics	2.00	Hold	$4.50	479.37% Upside

Current Analyst Ratings Breakdown

Latest BRNS, OTLK, KLRS, and ALDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/20/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/18/2026	OTLK Oncobiologics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/14/2026	KLRS Kalaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
5/14/2026	KLRS Kalaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
5/13/2026	KLRS Kalaris Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/13/2026	KLRS Kalaris Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$26.00 ➝ $25.00
5/8/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
4/22/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
4/16/2026	KLRS Kalaris Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$14.00
3/27/2026	OTLK Oncobiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.74 per share	N/A
BRNS Barinthus Biotherapeutics	$14.97M	1.78	N/A	N/A	$1.82 per share	0.36
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$4.21 per share	N/A
OTLK Oncobiologics	$1.35M	80.58	N/A	N/A	($0.60) per share	-1.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$33.85M	-$0.46	N/A	N/A	N/A	N/A	-57.34%	-36.33%	8/6/2026 (Estimated)
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.29	N/A	N/A	N/A	N/A	-63.83%	-48.77%	8/6/2026 (Estimated)
KLRS Kalaris Therapeutics	-$43.44M	-$2.15	N/A	N/A	N/A	N/A	-72.78%	-43.49%	N/A
OTLK Oncobiologics	-$62.42M	-$1.17	N/A	N/A	N/A	N/A	N/A	-291.28%	8/13/2026 (Estimated)

Latest BRNS, OTLK, KLRS, and ALDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2026	Q2 2026	OTLK Oncobiologics	-$0.12	-$0.16	-$0.04	-$0.05	$4.39 million	$0.13 million
5/12/2026	Q1 2026	KLRS Kalaris Therapeutics	-$0.52	-$0.46	+$0.06	-$0.46	N/A	N/A
5/7/2026	Q1 2026	ALDX Aldeyra Therapeutics	-$0.13	-$0.06	+$0.07	-$0.06	N/A	N/A
4/30/2026	Q1 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.14	+$0.14	-$0.14	N/A	N/A
3/17/2026	Q4 2025	KLRS Kalaris Therapeutics	-$0.56	-$0.44	+$0.12	-$0.44	N/A	N/A
3/13/2026	Q4 2025	BRNS Barinthus Biotherapeutics	-$0.40	-$0.27	+$0.13	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	2.72	2.72
BRNS Barinthus Biotherapeutics	N/A	6.05	6.05
KLRS Kalaris Therapeutics	N/A	12.19	12.19
OTLK Oncobiologics	N/A	0.54	0.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
BRNS Barinthus Biotherapeutics	25.20%
KLRS Kalaris Therapeutics	66.05%
OTLK Oncobiologics	11.20%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	11.80%
BRNS Barinthus Biotherapeutics	10.70%
KLRS Kalaris Therapeutics	68.10%
OTLK Oncobiologics	2.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	10	60.32 million	53.20 million	Optionable
BRNS Barinthus Biotherapeutics	107	40.85 million	36.48 million	N/A
KLRS Kalaris Therapeutics	110	23.79 million	7.59 million	N/A
OTLK Oncobiologics	20	140.05 million	136.13 million	Optionable

BRNS, OTLK, KLRS, and ALDX Headlines

Recent News About These Companies

Yezan Munther Haddadin Purchases 29,000 Shares of Oncobiologics (NASDAQ:OTLK) Stock

June 4 at 8:34 AM | insidertrades.com

Oncobiologics (NASDAQ:OTLK) Director Ghiath Sukhtian Buys 8,539,709 Shares

June 3 at 3:49 AM | americanbankingnews.com

Oncobiologics (NASDAQ:OTLK) Director Buys $5,038,428.31 in Stock

June 2 at 4:16 AM | insidertrades.com

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

June 1, 2026 | globenewswire.com

Oncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Hold" from Brokerages

June 1, 2026 | americanbankingnews.com

Oncobiologics (NASDAQ:OTLK) Rating Increased to Sell at Wall Street Zen

May 30, 2026 | americanbankingnews.com

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 28, 2026 | globenewswire.com

Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA

May 26, 2026 | benzinga.com

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

May 26, 2026 | globenewswire.com

Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates

May 15, 2026 | zacks.com

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

May 15, 2026 | globenewswire.com

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

April 23, 2026 | globenewswire.com

Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

April 22, 2026 | globenewswire.com

Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVAâ„¢ (bevacizumab-vikg)

April 21, 2026 | globenewswire.com

Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA

April 7, 2026 | globenewswire.com

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

March 25, 2026 | globenewswire.com

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

March 24, 2026 | globenewswire.com

Outlook Therapeutics Announces Proposed Public Offering

March 23, 2026 | globenewswire.com

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

March 16, 2026 | globenewswire.com

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

March 5, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS, OTLK, KLRS, and ALDX Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$1.63 -0.13 (-7.39%)

Closing price 04:00 PM Eastern

Extended Trading

$1.73 +0.10 (+6.26%)

As of 07:57 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Barinthus Biotherapeutics NASDAQ:BRNS

$0.65 -0.05 (-6.95%)

Closing price 03:59 PM Eastern

Extended Trading

$0.60 -0.06 (-8.60%)

As of 07:49 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Kalaris Therapeutics NASDAQ:KLRS

$4.44 -0.22 (-4.72%)

Closing price 04:00 PM Eastern

Extended Trading

$4.33 -0.11 (-2.57%)

As of 06:44 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Oncobiologics NASDAQ:OTLK

$0.78 -0.02 (-2.28%)

Closing price 04:00 PM Eastern

Extended Trading

$0.81 +0.03 (+4.03%)

As of 07:55 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BRNS, OTLK, KLRS, and ALDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BRNS, OTLK, KLRS, and ALDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BRNS, OTLK, KLRS, and ALDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS, OTLK, KLRS, and ALDX Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Barinthus Biotherapeutics NASDAQ:BRNS

Kalaris Therapeutics NASDAQ:KLRS

Oncobiologics NASDAQ:OTLK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BRNS, OTLK, KLRS, and ALDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BRNS, OTLK, KLRS, and ALDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BRNS, OTLK, KLRS, and ALDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS, OTLK, KLRS, and ALDX Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Barinthus Biotherapeutics NASDAQ:BRNS

Kalaris Therapeutics NASDAQ:KLRS

Oncobiologics NASDAQ:OTLK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools